Improving Lives
Lycia’s mission is to improve patients’ lives by stopping disease at its source. At the root of many diseases are dysregulated proteins that circulate in blood or are attached to the outside of the cell. Our novel platform addresses this issue and builds on research that revealed a new class of therapeutics – LYTAC degraders.
While our initial focus is on developing therapeutics that target and eliminate the drivers of autoimmune and inflammatory diseases, our technology can target many proteins that have been well validated as drivers of disease.
With our novel LYTAC degraders, we believe we can have a life-changing impact on patients who urgently need new options.
Our LYTAC platform has the potential to address a broad range of diseases
We developed the LYTAC platform to create therapeutics that can rapidly and selectively reduce the levels of disease-causing proteins. Our LYTAC therapeutics are modular and can be customized to target and eliminate different pathogenic proteins, including some previously considered undruggable. The versatility of the LYTAC platform opens the door to treating a broad spectrum of diseases.
Join our team
If you are interested in joining a team that is passionate about stopping disease at its source and have the experience and collaborative spirit to make a difference, click here to learn about our current opportunities.
